Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
They are better understood as a system
The major players in the obesity GLP-1 market include Novo Nordisk A/S, Eli Lilly and Company, Amgen, Viking Therapeutic, AstraZeneca, Roche (Carmot Therapeutics), Boehringer Ingelheim, Pfizer Inc., Altimmune, Inc., and Structure Therapeutics
Key features include: 99% purity, confirmed by HPLC and mass spectrometry for analytical accuracy and research reproducibility Pentapeptide structurewith non-proteinogenic residues (Aib and D-amino acids) conferring exceptional metabolic stability and resistance to non-specific proteolytic degradation High receptor selectivitydemonstrating minimal activity on non-target pituitary hormones including ACTH, cortisol, prolactin, FSH, LH, and TSHdistinguishing it from less selective growth hormone secretagogues Potent GHS-R1a agonist activitywith ED = 2.3 nmol/kg in conscious animal models, comparable to GHRP-6 efficacy but with enhanced selectivity Lyophilized powder formatproviding extended shelf-life stability of up to 24 months when stored appropriately, with minimal degradation under recommended cold-storage conditions Widely utilized as a pharmacological tool compoundfor structure-activity relationship (SAR) investigations and receptor-ligand selectivity studies For laboratory research use only How is Ipamorelin synthesized
Theoretically, slower dose increases might allow the nervous system to adapt more gradually to GLP-1 receptor activation
Instead, peptides like sermorelin and CJC-1295/Ipamorelin signal your pituitary gland to produce and release more of your own GH preserving the bodys natural feedback loops and dramatically reducing the risk profile compared to exogenous HGH
Always consult with your healthcare professional if you have persistent or worsening nausea
US$ 25.23
US$ 24.16
US$ 21.44
